Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
SLC22A5	6584	LEVOCARNITINE	CHEMBL1149		DrugBank	12181285, 12183691, 12644265, 12175785, 12635840

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
SLC22A5	rs2631372	CG + GG	imatinib	efficacy	yes	Carriers of the G allele had prolonged time to progression, which was calculated from the start of therapy to the date of disease progression as documented by a CT scan performed every 3-4 months.	Genotypes CG + GG are associated with increased response to imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.	23127916	982046735
SLC22A5	rs2631367	CG + GG	imatinib	efficacy	yes	Carriers of the G allele had prolonged time to progression, which was calculated from the start of therapy to the date of disease progression as documented by a CT scan performed every 3-4 months.	Genotypes CG + GG are associated with increased response to imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.	23127916	982046731
SLC22A5	rs2631372	G	imatinib	dosage	no	No significant association between genotype and chance of requiring an imatinib dose reduction.	Allele G is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.	30713339	1450933302
SLC22A5	rs2631367	C	imatinib	dosage	no	No significant association between genotype and chance of requiring an imatinib dose reduction.	Allele C is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.	30713339	1450933253
SLC22A5	rs2631370	C	imatinib	dosage	no	No significant association between genotype and chance of requiring an imatinib dose reduction.	Allele C is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele T.	30713339	1450933294